Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues (Q33386145)

26 July 2017

1 reference

title

Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues (English)

1 reference

heparin-induced thrombocytopenia

26 July 2017

1 reference

1 reference

based on heuristic

inferred from title

author name string

Allison Beck Blackmer

series ordinal

1

1 reference

26 July 2017

Maryann D Oertel

series ordinal

2

1 reference

26 July 2017

John M Valgus

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

8 September 2009

1 reference

Annals of Pharmacotherapy

26 July 2017

published in

1 reference

26 July 2017

volume

43

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

1636-1646

1 reference

Fondaparinux as a treatment option for heparin-induced thrombocytopenia

26 July 2017

cites work

1 reference

Clinical practice. Heparin-induced thrombocytopenia

21 January 2018

1 reference

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

Testing for heparin-induced thrombocytopenia antibodies

21 January 2018

1 reference

Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia

21 January 2018

1 reference

Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin

21 January 2018

1 reference

Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes

21 January 2018

1 reference

Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies

21 January 2018

1 reference

Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings

21 January 2018

1 reference

Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II.

21 January 2018

1 reference

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes

21 January 2018

1 reference

Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis.

21 January 2018

1 reference

Heparin-induced thrombocytopenia and phlegmasia cerulea dolens of the upper limb successfully treated with fondaparinux.

21 January 2018

1 reference

Heparin-induced thrombocytopenia successfully treated with fondaparinux

21 January 2018

1 reference

Anticoagulation in a Neurosurgical Patient with Heparin-Induced Thrombocytopenia Type II with Argatroban and Fondaparinux after Clipping of an Intracranial Aneurysm

21 January 2018

1 reference

Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis

21 January 2018

1 reference

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

Standardizing the management of heparin-induced thrombocytopenia

21 January 2018

1 reference

Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.

21 January 2018

1 reference

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux.

21 January 2018

1 reference

Recombinant activated factor VII for acute subdural haematoma in an elderly patient taking fondaparinux

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M136

1 reference

26 July 2017

1 reference